Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
HLS > SEC Filings for HLS > Form 8-K on 13-Nov-2012All Recent SEC Filings

Show all filings for HEALTHSOUTH CORP

Form 8-K for HEALTHSOUTH CORP


13-Nov-2012

Regulation FD Disclosure


ITEM 7.01. Regulation FD Disclosure.
Subsequent to its earnings release for the third quarter of 2012, HealthSouth Corporation ("HealthSouth" or the "Company") assembled an Investor Reference Book, which is attached to this Current Report on Form 8?K as Exhibit 99.1 (the "Investor Reference Book"). The Investor Reference Book addresses, among other things, an overview of the Company and its industry, a historical perspective of the Company, the Company's business outlook, the Company's financial and operational metrics and initiatives, and the Company's value proposition. The Investor Reference Book is available at http://investor.healthsouth.com by clicking on an available link.
The Company will participate in the Lazard Capital Markets 9th Annual Healthcare Conference held at The Pierre Hotel in New York on November 13-14, 2012. HealthSouth President and Chief Executive Officer, Jay Grinney, will make a presentation on Wednesday, November 14th at 9:30 a.m. ET using information included in the Investor Reference Book.

The Company will also participate in the Citi 2012 North American Credit Conference held at the Waldorf Astoria in New York on November 14-15, 2012. HealthSouth Executive Vice President and Chief Financial Officer, Doug Coltharp, will make a presentation on Wednesday, November 14th at 10:50 a.m. ET using information included in the Investor Reference Book.
Both presentations will address, among other things, the Company's strategy and financial performance and discuss
industry trends and dynamics. The presentations will be webcast live and will be available at http://investor.healthsouth.com by clicking on an available link. While the format of certain slides may have changed, the slides used in the presentations contain much of the same information as included in the Investor Reference Book.
The Company will also provide its observations and considerations for the fourth quarter of 2012. These observations
and considerations are:

         Volume: As anticipated, discharge growth in October 2012 was positively
          impacted by an increased length of stay at the end of September which
          rolled discharges into October. Discharge growth in November and
          December is difficult to predict due to the holiday season.


         Storm Sandy: The bulk of the storm-related disruption was limited to
          two hospitals, our Toms River and Tintin Falls hospitals in New Jersey.
          The Company does not expect the storm to have a material effect on the
          Company's earnings in the fourth quarter of 2012.

The Company reiterates as of the date hereof its guidance for 2012, as previously reported in the press release furnished as an exhibit to the Current Report on Form 8-K dated October 25, 2012 and during the Company's earnings conference call held on October 26, 2012.
The Company uses "same-store" comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on hospitals open throughout both the full current periods and throughout the full prior periods presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company's results of operations. The information contained in this Item 7.01 is being furnished pursuant to Item 7.01 of Form 8-K, "Regulation FD Disclosure." This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Note Regarding Presentation of Non-GAAP Financial Measures The financial data contained in the Investor Reference Book attached as Exhibit 99.1 includes non-GAAP financial measures, including the Company's leverage ratio and Adjusted EBITDA. The leverage ratio referenced therein is defined as the ratio of consolidated total debt to Adjusted EBITDA for the trailing four quarters. The Company believes its leverage ratio and Adjusted EBITDA are measures of its ability to service its debt and its ability to make capital expenditures. Additionally, the leverage ratio is a standard measurement used by investors to gauge the creditworthiness of an institution. The Company's credit agreement also includes a maximum leverage ratio financial covenant which allows the Company to deduct up to $75 million of cash on hand from consolidated total debt. The Company reconciles Adjusted EBITDA to net income and to net cash provided by operating activities.


The Company uses Adjusted EBITDA on a consolidated basis as a liquidity measure. The Company believes this financial measure on a consolidated basis is important in analyzing its liquidity because it is the key component of certain material covenants contained within the Company's credit agreement, which is discussed in more detail in Note 8, Long-term Debt, to the consolidated financial statements included in its Annual Report on Form 10?K for the year ended December 31, 2011 (the "2011 Form 10?K"). These covenants are material terms of the credit agreement. Non-compliance with these financial covenants under the credit agreement-its interest coverage ratio and its leverage ratio-could result in the Company's lenders requiring the Company to immediately repay all amounts borrowed. If the Company anticipated a potential covenant violation, it would seek relief from its lenders, which would have some cost to the Company, and such relief might not be on terms favorable to those in the Company's existing credit agreement. In addition, if the Company cannot satisfy these financial covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the Company's assessment of its liquidity.
In general terms, the credit agreement definition of Adjusted EBITDA, referred to as "Adjusted Consolidated EBITDA" there, allows the Company to add back to consolidated net income interest expense, income taxes, and depreciation and amortization and then add back to consolidated net income (1) all unusual or non-recurring items reducing consolidated net income (of which only up to $10 million in a year may be cash expenditures), (2) costs and expenses related to refinancing transactions (in years prior to 2012), (3) any losses from discontinued operations and closed locations, (4) costs and expenses, including legal fees and expert witness fees, incurred with respect to litigation associated with stockholder derivative litigation, including the matters related to Ernst & Young LLP and Richard Scrushy discussed in Note 21, Settlements, and Note 22, Contingencies and Other Commitments, to the consolidated financial statements accompanying the 2011 Form 10-K and Note 9, Contingencies, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of the Company's quarterly report on Form 10-Q for the quarterly period ended September 30, 2012 (the "September 2012 Form 10-Q"), and (5) share-based compensation expense. The Company also subtracts from consolidated net income all unusual or non-recurring items to the extent increasing consolidated net income.
Under the credit agreement, the Adjusted EBITDA calculation does not include adjustments for the following items: (1) net income attributable to noncontrolling interests, (2) gain or loss on disposal of assets,
(3) professional fees unrelated to the stockholder derivative litigation, and
(4) unusual or non-recurring cash expenditures in excess of $10 million. These items may not be indicative of the Company's ongoing performance, so the Adjusted EBITDA calculation presented here includes adjustments for them. Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America ("GAAP"), and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for net income or cash flows from operating, investing, or financing activities. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note 1, Summary of Significant Accounting Policies, to the consolidated financial statements accompanying the 2011 Form 10?K. The Company also uses adjusted free cash flow as an analytical indicator to assess its performance. Management believes the presentation of adjusted free cash flow provides investors an efficient means by which they can evaluate the Company's capacity to reduce debt and pursue development activities. The calculation of adjusted free cash flow is included in the Investor Reference Book attached as Exhibit 99.1. This measure is not a defined measure of financial performance under GAAP and should not be considered as an alternative to net cash provided by operating activities. The Company's definition of adjusted free cash flow is limited and does not represent residual cash flows available for discretionary spending. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. See the consolidated statements of cash flows included in the 2011 Form 10-K and the condensed consolidated statements of cash flows included in the September 2012 Form 10-Q for the GAAP measures of cash flows from operating, investing, and financing activities. A reconciliation of net cash provided by operating activities to adjusted free cash flow is included in the Investor Reference Book attached as Exhibit 99.1.


Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA

                        Three Months Ended         Nine Months Ended
                          September 30,              September 30,                         Year Ended December 31,
                         2012         2011         2012         2011        2011        2010        2009        2008        2007
                                                                     (In Millions)
Net cash provided by
operating activities $   107.2      $  55.1     $   302.2     $ 213.2     $ 342.7     $ 331.0     $ 406.1     $ 227.2     $ 230.6
Provision for
doubtful accounts         (7.0 )       (5.1 )       (19.8 )     (14.9 )     (21.0 )     (16.4 )     (30.7 )     (23.0 )     (28.5 )
Professional
fees-accounting,
tax, and legal             4.1          4.0          13.2        16.2        21.0        17.2         8.8        44.4        51.6
Interest expense and
amortization of debt
discounts and fees        23.5         26.3          69.8        96.3       119.4       125.6       125.7       159.3       229.2
UBS Settlement
proceeds, gross              -            -             -           -           -           -      (100.0 )         -           -
Equity in net income
of nonconsolidated
affiliates                 3.3          3.1           9.7         8.8        12.0        10.1         4.6        10.6        10.3
Net income
attributable to
noncontrolling
 interests in
continuing
operations               (12.8 )      (11.4 )       (38.6 )     (34.5 )     (47.0 )     (40.9 )     (33.3 )     (29.8 )     (31.1 )
Amortization of debt
discounts and fees        (0.9 )       (0.9 )        (2.7 )      (3.3 )      (4.2 )      (6.3 )      (6.6 )      (6.5 )      (7.8 )
Distributions from
nonconsolidated
affiliates                (2.4 )       (4.2 )        (7.9 )      (9.7 )     (13.0 )      (8.1 )      (8.6 )     (10.9 )      (5.3 )
Current portion of
income tax (benefit)
expense                   (0.6 )       (0.1 )         3.7        (1.5 )       0.6         2.9        (7.0 )     (72.8 )    (330.4 )
Change in assets and
liabilities               13.0         37.4          51.4        65.7        49.9         2.8        (2.1 )      50.6         5.5
Net premium paid on
bond
issuance/redemption          -          8.9             -        22.8        22.8           -           -           -           -
Change in
government, class
action,
and related
settlements
liability                 (2.6 )          -          (2.6 )      (6.5 )      (8.5 )       2.9        11.2         7.4       171.4
Net cash used in
(provided) by
operating
activities of
discontinued
operations                 0.2         (2.2 )        (1.5 )      (9.4 )      (9.1 )     (13.2 )      (5.7 )     (32.5 )      (3.3 )
Other, including
realized losses and
(gains)
 on sales of
investments                0.2         (0.4 )         0.4         0.1         0.6         2.0         1.3        (1.4 )      14.5
Adjusted EBITDA      $   125.2      $ 110.5     $   377.3     $ 343.3     $ 466.2     $ 409.6     $ 363.7     $ 322.6     $ 306.7


For the three months ended September 30, 2012, net cash used in investing activities was $36.0 million and resulted primarily from capital expenditures. Net cash provided by financing activities during the three months ended September 30, 2012 was $50.8 million and resulted primarily from net proceeds from debt transactions offset by distributions paid to noncontrolling interests of consolidated affiliates and dividends paid on the Company's convertible perpetual preferred stock.
For the three months ended September 30, 2011, net cash provided by investing activities was $81.9 million and resulted primarily from proceeds from the sale of five long-term acute care hospitals in August 2011. Net cash used in financing activities during the three months ended September 30, 2011 was $149.6 million and resulted primarily from net debt payments, including the September 2011 optional redemption of $165.6 million of the Company's 10.75% Senior Notes due 2016.
For the nine months ended September 30, 2012, net cash used in investing activities was $124.3 million and resulted primarily from capital expenditures. Net cash used in financing activities during the nine months ended September 30, 2012 was $44.8 million and resulted primarily from repurchases of 46,645 shares of the Company's convertible perpetual preferred stock, distributions paid to noncontrolling interests of consolidated affiliates, and dividends paid on the Company's convertible perpetual preferred stock offset by net proceeds from debt transactions and capital contributions from consolidated affiliates. For the nine months ended September 30, 2011, net cash provided by investing activities was $32.7 million and resulted primarily from the proceeds from the sale of five long-term acute care hospitals in August 2011 offset by capital expenditures and net settlement payments related to interest rate swaps. Net cash used in financing activities during the nine months ended September 30, 2011 was $246.6 million and resulted primarily from net debt payments, including the optional redemption of the Company's 10.75% Senior Notes due 2016, distributions paid to noncontrolling interests of consolidated affiliates, and dividends paid on the Company's convertible perpetual preferred stock. For the year ended December 31, 2011, net cash used in investing activities was $24.6 million and resulted primarily from capital expenditures, net settlement payments related to interest rate swaps, and purchases of restricted investments offset by proceeds from the sale of five long-term acute care hospitals in August 2011. Net cash used in financing activities during the year ended December 31, 2011 was $336.4 million and resulted primarily from net debt payments, including the optional redemption of the Company's 10.75% Senior Notes due 2016, distributions paid to noncontrolling interests of consolidated affiliates, and dividends paid on the Company's convertible perpetual preferred stock.
For the year ended December 31, 2010, net cash used in investing activities was $125.9 million and resulted primarily from capital expenditures, net settlement payments related to interest rate swaps, acquisitions of businesses, and net purchases of restricted investments offset by a decrease in restricted cash and proceeds from the sale of our hospital in Baton Rouge. Net cash used in financing activities during the year ended December 31, 2010 was $237.7 million and resulted primarily from net debt payments, distributions paid to noncontrolling interests of consolidated affiliates, dividends paid on the Company's convertible perpetual preferred stock, and debt amendment and issuance costs.
For the year ended December 31, 2009, net cash used in investing activities was $133.0 million and resulted primarily from capital expenditures and net settlement payments related to interest rate swaps. Net cash used in financing activities during the year ended December 31, 2009 was $224.3 million and resulted primarily from net debt payments, distributions paid to noncontrolling interests of consolidated affiliates, dividends paid on the Company's convertible perpetual preferred stock, and debt amendment and issuance costs. For the year ended December 31, 2008, net cash used in investing activities was $40.0 million and resulted primarily from capital expenditures, including expenditures associated with development activities, and net settlement payments related to an interest rate swap offset by proceeds from asset disposals, including our corporate campus. Net cash used in financing activities during the year ended December 31, 2008 was $176.0 million and resulted primarily from net debt payments made during the period, as well as distributions paid to noncontrolling interests of consolidated affiliates and dividends paid on the Company's perpetual preferred stock, offset by proceeds from the issuance of common stock.
For the year ended December 31, 2007, net cash provided by investing activities was $1,184.5 million and resulted primarily from the proceeds from the divestitures of the Company's surgery centers, outpatient, and diagnostic divisions. Net cash used in financing activities during the year ended December 31, 2007 was $1,436.6 million and resulted primarily from net debt payments primarily using the net proceeds from the divestitures discussed above. Forward-Looking Statements
Statements contained in this document and the Investor Reference Book attached as Exhibit 99.1 which are not historical facts are forward-looking statements. In addition, HealthSouth, through its senior management, may from time to


time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and HealthSouth undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information, involve a number of risks and uncertainties, and relate to, among other things, future events, HealthSouth's plan to repurchase its debt or equity securities, dividend strategies, effective income tax rates, HealthSouth's business strategy, its financial plans, its future financial performance, or its projected business results or model, or its projected capital expenditures. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by HealthSouth include, but are not limited to, any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings involving the Company, including the Houston HHS-OIG investigation; significant changes in HealthSouth's management team; HealthSouth's ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with its growth strategy; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for HealthSouth's services by governmental or private payors; changes in the regulation of the healthcare industry at either or both of the federal and state levels, including as part of national healthcare reform and deficit reduction; competitive pressures in the healthcare industry and HealthSouth's response thereto; potential disruptions or incidents affecting the proper operation, availability, or security of our information systems; HealthSouth's ability to obtain and retain favorable arrangements with third-party payors; HealthSouth's ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages and the impact on HealthSouth's labor expenses from potential union activity and staffing shortages; general conditions in the economy and capital markets; the increase in the costs of defending and insuring against alleged professional liability claims and our ability to predict the estimated costs related to such claims; and other factors which may be identified from time to time in HealthSouth's SEC filings and other public announcements, including HealthSouth's Form 10-K for the year ended December 31, 2011 and Form 10-Q for the quarters ended September 30, 2012, June 30, 2012, and March 31, 2012. ITEM 9.01. Financial Statements and Exhibits.
(d) Exhibits
99.1 HealthSouth Corporation Investor Reference Book - Post Q3 2012 Earnings Release.


  Add HLS to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for HLS - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.